跳转到内容

阿伏利尤单抗

维基百科，自由的百科全书
阿伏利尤单抗
单克隆抗体
种类完整抗体
目标第一型干扰素受体（英语：Interferon-alpha/beta receptor）
临床资料
商品名（英语：Drug nomenclature）Saphnelo
其他名称MEDI-546, anifrolumab-fnia
AHFS/Drugs.comMonograph
核准状况
怀孕分级
给药途径静脉注射
药物类别（英语：Drug class）第一型干扰素受体（英语：Interferon-alpha/beta receptor）阻断剂
ATC码
法律规范状态
法律规范
识别信息
CAS号1326232-46-5
DrugBank
ChemSpider
  • none
UNII
KEGG
化学信息
化学式C6444H9964N1712O2018S44
摩尔质量145,119.20 g·mol−1

阿伏利尤单抗（英语：Anifrolumab）商品名为莎芙诺（英语：Saphnelo），用于治疗全身性红斑狼疮[7]。适用于常规治疗无法控制的中度至重度病症[7]。透过静脉注射给药[7]。

最常见的副作用是上呼吸道感染和支气管炎[8]。其他副作用包括可能带状疱疹[8]。妊娠期的安全性不明[7]。它是一种单克隆抗体，与第一型干扰素受体（英语：Interferon-alpha/beta receptor）结合，并阻断第一型干扰素（英语：Interferon type I）的作用[8]。

阿伏利尤单抗分别于2021年与2022年获得美国与欧洲的医疗使用许可[7] [8]。美国食品药品监督管理局将它视为同类新创药（英语：First-in-class medication）[9]。

命名

[编辑]

阿伏利尤单抗是国际非专利名称 (international nonproprietary name，INN)。[10]

参考文献

[编辑]
  1. ^ 1.0 1.1 Saphnelo APMDS. Therapeutic Goods Administration (TGA). 12 April 2022 [24 April 2022]. （原始内容存档于19 September 2022）. 
  2. ^ Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 21 December 2022 [2 January 2023]. 
  3. ^ Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24]. Health Canada. 24 January 2022 [28 May 2022]. （原始内容存档于29 May 2022）. 
  4. ^ Summary Basis of Decision (SBD) for Saphnelo. Health Canada. 23 October 2014 [29 May 2022]. （原始内容存档于29 May 2022）. 
  5. ^ Saphnelo- anifrolumab injection, solution. DailyMed. [11 August 2021]. （原始内容存档于12 August 2021）. 
  6. ^ Saphnelo EPAR. European Medicines Agency. 16 December 2021 [11 April 2022]. （原始内容存档于12 April 2022）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ 7.0 7.1 7.2 7.3 7.4 Saphnelo- anifrolumab injection, solution. DailyMed. [11 August 2021]. （原始内容存档于12 August 2021）. 
  8. ^ 8.0 8.1 8.2 8.3 Saphnelo EPAR. European Medicines Agency. 16 December 2021 [11 April 2022]. （原始内容存档于12 April 2022）.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  9. ^ Advancing Health Through Innovation: New Drug Therapy Approvals 2021. U.S. Food and Drug Administration (FDA) (报告). 13 May 2022 [22 January 2023]. （原始内容 (PDF)存档于6 December 2022）. 
  10. ^ World Health Organization. International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71. WHO Drug Information. 2014, 28 (1). hdl:10665/331151 可免费查阅. 

延伸阅读

[编辑]

外部连节

[编辑]
  • Clinical trial number NCT01438489 for "A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus" at ClinicalTrials.gov
  • Clinical trial number NCT02446912 for "Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus" at ClinicalTrials.gov
  • Clinical trial number NCT02446899 for "Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus" at ClinicalTrials.gov


检索自“https://zh.wikipedia.org/w/index.php?title=阿伏利尤單抗&oldid=84862111”